Ignite Creation Date:
2025-12-25 @ 4:19 AM
Ignite Modification Date:
2026-01-22 @ 7:57 PM
Study NCT ID:
NCT01752920
Status:
COMPLETED
Last Update Posted:
2023-06-05
First Post:
2012-12-14
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Sponsor:
Basilea Pharmaceutica
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ARQ 087-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |